American Diabetes Association: National Diabetes Statistics Report 2014. Centers for Disease Control. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 23 July 1, 2014.
Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al: The global burden of diabetic foot disease. Lancet 366: 1719, 2005.
Frykberg RG, Zgonis T, Armstrong DG, et al: Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg 45(5 Suppl): S1, 2006.
Palumbo PJ, Melton LJ: “Peripheral vascular disease and diabetes,” in Diabetes In America , edited by MI Harris and RF Hamman, p 1, National Institutes of Health, Bethesda, 1985.
Reiber GE: “Epidemiology of foot ulcers and amputations in the diabetic foot, “ In: The Diabetic Foot , edited by JH Bowker and MA Pfeifer, p 13, Mosby, St. Louis, 2001.
Reiber GE, Boyko EJ, Smith DG: “Lower extremity foot ulcers and amputations in diabetes,” in Diabetes in America , 2nd Ed, edited by MI Harris, C Cowie, MP Stern, p 409, NIH Publication No. 95-1468, 1995.
Frykberg RG, Habershaw GM, Chrzan JS: “Epidemiology of the diabetic foot: ulcerations and amputations,” in Contemporary Endocrinology: Clinical Management of Diabetic Neuropathy , edited by A Veves, p 273, Humana Press, Totowa, 1998.
American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care 31: 596, 2008.
American Diabetes Association: Economic costs of diabetes in the US in 2002. Diabetes Care 26: 917, 2003.
Sedory Holzer SE, Camerota A, Martens L, et al: Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 20: 169, 1998.
Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13: 513, 1990.
Larsson J, Agardh CD, Apelqvist J, et al: Long-term prognosis after healed amputation in patients with diabetes. Clin Orthop Relat Res 350: 149, 1998.
American Diabetes Association: Consensus development conference on diabetic foot wound care. Diabetes Care 22: 1354, 1999.
Margolis DJ, Allen-Taylor L, Hoffstad O, et al: Diabetic neuropathic foot ulcers and amputation. Wound Repair Regen 13: 230, 2005.
Rice JB, Desai U, Cummings AKG, et al: Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care 37: 651, 2014
Steed DL, Donohoe D, Webster MW, et al: Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 183: 61, 1996.
Wieman TJ, Griffiths GD, Polk HC, et al: Management of diabetic midfoot ulcers. Ann Surg 15: 627, 1992.
Teng YJ, Li YP, Wang JW, et al: Bioengineered skin in diabetic foot ulcers. Diabetes Obes Metab 12: 307, 2010.
Mulder G, Armstrong DG, Seaman S: Standard appropriate and advanced care: medical legal considerations for diabetic lower extremity wounds. Wounds 26: 1069, 2003.
Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 46: 155, 1986.
Ross R: Platelet-derived growth factor. Lancet 1: 1179, 1989.
Pierce GF, Mustoe TA, Altrock BW, et al: Role of platelet-derived growth factor in wound healing. J Cell Biochem 45: 319, 1991.
Kiritsy CP, Lynch AB, Lynch SE: Role of growth factors in cutaneous wound healing: a review. Crit Rev Oral Biol Med 4: 729, 1993.
Bennett NT, Schultz GS: Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 166: 74, 1993.
Grotendorst GR, Martin GR, Pencey D, et al: Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J Clin Invest 76: 2323, 1985.
Wieman TJ: Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg 176 (2A Suppl): 74S, 1998.
Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21: 822, 1998.
Knighton DR, Ciresi KF, Fiegel VD, et al: Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 204: 332, 1986.
Smiell JM, Wieman J, Steed DL, et al: Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg 7: 335, 1999.
Steed D: “Modulating wound healing in diabetes,” in The Diabetic Foot, edited by J Bowker, M Pfeiffer, p 395, Mosby, St. Louis, 2001.
Falanga V, Shen J: “Growth factors, signal transduction and cellular responses,” in Cutaneous Wound Healing , edited by V Falanga, p 81, Martin Dunitz Ltd, London, 2001.
Robson M, Smith P: “Topical use of growth factors to enhance healing,” in Cutaneous Wound Healing , edited by V Falanga, p 379, Martin Dunitz Ltd, London, 2001.
Hogge J, Krasner D, Nguyen HC, et al: The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. JAPMA 90: 57, 2000.
Rovee DT, Kurowsky CA, Labun J: Local wound environment and epidermal healing. Arch Dermatol 106: 330, 1972.
D'Hemecourt PA, Smiell JM, Hugill JV, et al: The effect of topically applied sodium carboxymethyl cellulose gel on non healing lower extremity ulcers in patients with diabetes. Wounds 10: 69, 1998.
Steed DL, The Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 21: 71, 1995.
Bhansali A, Venkatesh H, Dutta P, et al: Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast? Diabetes Res Clin Pract 83: 13, 2009.
Hardikar JV: Efficacy of recombinant human platelet derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India. Wounds 17: 141, 2005.
Sibbald RG, Torrance G, Hux M, et al: Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage 49: 76, 2003.
Ghatnekar O, Persson U, Willis M, et al: Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 19: 767, 2001.
Margolis DJ, Gelfand JM, Hoffstad O, et al: Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 26: 1696, 2003.
Lantis JC II, Boone D, Gendics C, et al: Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care 22: 167, 2009.
American Medical Association: Current Procedural Terminology. American Medical Association. Available at: http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt.page. Accessed June 25, 2014.
Regranex Directions for Use. Smith & Nephew Biotherapeutics, Inc. Available at: http://www.regranex.com/. Accessed June 25, 2014.
Cardinal M, Phillips T, Eisenbud DE, et al: Nonlinear modeling of venous leg ulcer healing rates. BMC Dermatology 9: 1, 2009.
Gillman T: Wound outcomes: the utility of surface measures. Low Extrem Wounds 3: 125, 2004.
Robson MC, Hill D, Woodske M, et al: Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Dermatol 135: 773, 2000.
Margolis DJ, Malay DS, Hoffstad OJ, et al: Economic burden of diabetic foot ulcers and amputations: Data points #3. Agency for Healthcare Research and Quality, Rockville, 2011.
Fife CE, Carter MJ, Walker D: Why is it so hard to do the right thing in wound care? Wound Rep Reg 18: 154, 2010.
Allenet B, Paree F, Lebrun T, et al: Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 26: 125, 2000.
US Government GPO: Tax Relief and Health Care Act of 2006. United States Congress, 2006. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-109publ432/pdf/PLAW-109publ432.pdf. Accessed December 8, 2014.
Persson U, Willis M, Odegaard K, et al: The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health 3(Suppl 1): S39, 2000.
Albert S: Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 19: 483, 2002.
Kantor J, Margolis DJ: Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 27: 347, 2001.
Warriner RA III, Driver VR: The true cost of growth factor therapy in diabetic foot ulcer care. Wounds (Supplement): S1, 2006.
Papanas N, Maltezos E: Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 3: 233, 2008.
Background: A comparison of the cost-effectiveness of becaplermin plus good wound care (BGWC) versus good wound care (GWC) alone in treating patients with diabetic foot ulcers (DFUs) may enable physicians and health-care decision makers in the United States to make better-informed choices about treating DFUs, which currently contribute to a substantial portion of the economic burden of diabetes.
Methods: Data from three phase III trials were used to predict expected 1-year costs and outcomes, including the average percentage reduction from baseline in wound surface area (WSA), the direct costs of DFU therapy, and the cost per cm2 of WSA reduction.
Results: At 20 weeks, the BGWC group had a statistically greater probability of complete wound closure than the GWC group (50% versus 35%; P = .015). Based on reported WSA reduction rates, DFUs in the BGWC group were predicted to close by 100% at 27 weeks, and those in the GWC group were predicted to close by 88% at 52 weeks. The GWC group had higher total estimated 1-year direct cost of DFU care ($6,809 versus $4,414) and higher cost per cm2 of wound closure ($3,501 versus $2,006).
Conclusions: Becaplermin plus good wound care demonstrated economic dominance compared with GWC by providing better clinical outcomes via faster reduction in WSA and higher rates of closure at a lower direct cost.